Relapsed Multiple Myeloma
Conditions
Brief summary
To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma
Interventions
DRUGCarfilzomib
Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
DRUGLenalidomide
Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
DRUGDexamethasone
Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
Sponsors
Amgen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Disease related: 1. Symptomatic multiple myeloma 2. Relapsed or progressive disease after at least one but no more than three prior therapeutic treatments or regimens for multiple myeloma 3. Prior therapeutic treatment regimens may have included bortezomib, lenalidomide, and/or thalidomide, among other agents. 4. If previously treated with lenalidomide or bortezomib, the subject must not have progressed during the first 3 months of treatment with the drug and must not have discontinued treatment due to lenalidomide intolerance (bortezomib intolerant subjects may enroll). 5. Measurable disease, as indicated by one or more of the following: * Serum M-protein ≥ 0.5 g/dL * Urine Bence-Jones protein ≥ 200 mg/24 h * If Serum Protein Electrophoresis is felt to be unreliable for routine M-protein measurement (particularly for patients with Immunoglobulin (Ig)A multiple myeloma), then quantitative immunoglobulin levels can be accepted. 6. Prior to enrollment, sites must provide evidence of myeloma progression/relapse, with start and stop dates of the most recent treatment regimen, as well as best tumor response to all prior treatment regimens. Demographic 7. Males and females ≥ 18 years of age 8. Life expectancy of more than three months 9. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 Laboratory 10. Adequate hepatic function, with bilirubin \< 2 times the upper limit of normal (ULN) and alanine aminotransferase (ALT) \< 3 times ULN 11. Absolute neutrophil count (ANC) ≥ 1,000/mm³, hemoglobin ≥ 8 gm/dL, platelet count ≥ 50,000/ mm³ (≥ 30 × 10\^9/L if myeloma involvement in the bone marrow is \> 50%) * Screening ANC should be independent of granulocyte- and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks. * Subjects may receive red blood cell (RBC) or platelet transfusions, if clinically indicated, in accordance with institutional guidelines * Screening platelet count should be independent of platelet transfusions for at least 2 weeks 12. Calculated or measured creatinine clearance of ≥ 50 mL/minute, calculated using the formula of Cockcroft and Gault \[(140 - Age) x Mass (kg) / (72 x creatinine mg/dL)\]; multiply result by 0.85 (if female). Other generally accepted calculation methods can be substituted. Ethical/Other 13. Written informed consent in accordance with federal, local, and institutional guidelines 14. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing 15. FCBP\* must have a negative serum or urine pregnancy test, with a sensitivity of at least 50 mIU/mL within 10-14 days (US/RevAssist®) or 25 mIU/mL within 7-14 days (Canada/RevAidSM), prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or to use two methods of reliable birth control, including at least one highly effective method AND one additional effective method of birth control (contraception) AT THE SAME TIME, beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during therapy delay, and continuing for 4 weeks following discontinuation of lenalidomide therapy. If a hormonal method (birth control pills, injections, patch or implants) or intrauterine device (IUD) is not medically possible for the subject, the subject may use another highly effective method or two barrier methods AT THE SAME TIME. 16. Male subjects must agree to NEVER have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant, or he must use a latex condom EVERY TIME he engages in any sexual contact with females who are pregnant or may become pregnant while he is taking lenalidomide and for 4 weeks after he stops taking the drug, even if he has had a successful vasectomy. The subject must agree to inform his physician if he has had unprotected sexual contact with a female who can become pregnant or if he thinks FOR ANY REASON, that his sexual partner may be pregnant. 17. Male subjects cannot donate semen or sperm while taking lenalidomide. 18. All study participants must be registered into the mandatory RevAssist (US) or RevAid (Canada) programs and be willing and able to comply with the requirements of Rev Assist/RevAid 19. Subjects must adhere to the study visit schedule and other protocol requirements and receive outpatient treatment and laboratory monitoring at the institute that administers the drug 20. Subjects must agree to take enteric-coated aspirin 81-325 mg orally daily, or if history of prior thrombotic disease or allergy to aspirin, must be fully anticoagulated with warfarin (INR 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism.
Exclusion criteria
Disease related 1. Subjects with non-secretory or hyposecretory multiple myeloma, defined as \< 0.5 g/dL M-protein in serum, \< 200 mg/24 hr Bence Jones protein in urine, or disease only measured by serum free light chain (FLC) 2. Subjects who never achieved at least a durable minimal response (MR, ≥ 25% reduction in M-protein for at least 6 weeks) on any prior therapy 3. Corticosteroid therapy in a dose equivalent to dexamethasone ≥ 4 mg/day or prednisone ≥ 20 mg/day within 3 weeks prior to first dose 4. Use of any other experimental drug or therapy within 28 days of baseline 5. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 6. Plasma cell leukemia 7. Waldenström's macroglobulinemia 8. Chemotherapy with approved or investigative anticancer therapeutics, including steroid therapy dose as defined above, within 3 weeks prior to first dose 9. Radiation therapy or immunotherapy within 4 weeks prior to first dose; localized radiation therapy within 1 week prior to first dose 10. Planned radiation therapy that occurs after the start of treatment 11. Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater. Concurrent conditions 12. Pregnant or lactating females 13. History of allergy to boron or mannitol 14. Major surgery within 3 weeks prior to first dose 15. Congestive heart failure (New York Heart Association class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months 16. Uncontrolled hypertension 17. Acute active infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose 18. Known or suspected human immunodeficiency virus (HIV) infection, known HIV seropositivity, or active hepatitis A, B, or C infection 19. Non-hematologic malignancy within the past three years except 1. adequately treated basal cell or squamous cell skin cancer, 2. carcinoma in situ of the cervix, or 3. prostate cancer \< Gleason Grade 6 with stable prostate specific antigen (PSA) levels 20. Serious psychiatric or medical conditions that could interfere with treatment 21. Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment 22. Contraindication to any of the required concomitant drugs, including proton-pump inhibitor (e.g., lansoprazole), enteric-coated aspirin or other anticoagulant, or if a history of prior thrombotic disease, warfarin or low molecular weight heparin 23. Subjects in whom the required program of oral and intravenous fluid hydration is contraindicated, e.g., due to pre-existing pulmonary, cardiac, or renal impairment 24. Subjects with known or suspected amyloidosis 25. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis 26. Prior carfilzomib treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months. | Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy. |
| Number of Participants With Dose-limiting Toxicities | Cycle 1, 28 days | Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic * ≥ Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy * ≥ Grade 4 fatigue persisting \> 7 days * Treatment delay for toxicity \> 21 days Hematologic * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) \> 7 days * Febrile neutropenia (ANC \< 1,000/mm³ with fever ≥ 38.3ºC) * Grade 4 thrombocytopenia (platelets \< 25,000/mm³) for \> 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding * Treatment delay for toxicity \> 21 days. The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort. |
Countries
Canada, United States
Participant flow
Recruitment details
This was an open-label study of carfilzomib (CFZ) given in combination with lenalidomide (LEN) and low-dose dexamethasone (DEX) in patients with relapsed multiple myeloma. The study consisted of a dose-escalation portion and an expansion portion. Participants were treated until disease progression (PD) or unacceptable toxicity.
Pre-assignment details
In the dose-escalation portion, participants were enrolled in sequential cohorts to determine the maximum tolerated doses (MTD) of carfilzomib and lenalidomide. In the expansion portion either the MTD or the maximum planned dose (MPD) from Cohort 6 (if no MTD was determined) was administered to gain additional safety and efficacy information.
Participants by arm
| Arm | Count |
|---|---|
| 1: CFZ 15 mg/m² + LEN 10 mg Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 10 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion. | 6 |
| 2: CFZ 15 mg/m² + LEN 15 mg Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 15 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion. | 6 |
| 3: CFZ 15 mg/m² + LEN 20 mg Treatment during Cycles 1 through 12 consisted of carfilzomib 15 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 20 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion. | 8 |
| 4: CFZ 20 mg/m² + LEN 20 mg Treatment during Cycles 1 through 12 consisted of carfilzomib 20 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 20 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15, and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion. | 6 |
| 5: CFZ 20 mg/m² + LEN 25 mg Treatment during Cycles 1 through 12 consisted of carfilzomib 20 mg/m² on Days 1, 2, 8, 9, 15, and 16; lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion. | 6 |
| 6: CFZ 20/27 mg/m² + LEN 25 mg Treatment consisted of carfilzomib 20 mg/m² on Days 1 and 2 of Cycle 1, followed by 27 mg/m² for the remainder of treatment (Days 8, 9, 15, and 16 of Cycle 1 and Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles); lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion. | 8 |
| 7: CFZ 20/27 mg/m² + LEN 25 mg In the Expansion portion, treatment consisted of carfilzomib 20 mg/m² on Days 1 and 2 of Cycle 1, followed by 27 mg/m² for the remainder of treatment (Days 8, 9, 15, and 16 of Cycle 1 and Days 1, 2, 8, 9, 15, and 16 for all subsequent cycles); lenalidomide 25 mg on Days 1 to 21; and 40 mg dexamethasone on Days 1, 8, and 15 and 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion. | 44 |
| Total | 84 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 1 | 1 | 2 | 1 | 2 | 10 |
| Overall Study | Other | 0 | 0 | 1 | 0 | 3 | 0 | 13 |
| Overall Study | Withdrew Consent | 0 | 2 | 0 | 0 | 1 | 0 | 1 |
Baseline characteristics
| Characteristic | Total | 7: CFZ 20/27 mg/m² + LEN 25 mg | 6: CFZ 20/27 mg/m² + LEN 25 mg | 5: CFZ 20 mg/m² + LEN 25 mg | 4: CFZ 20 mg/m² + LEN 20 mg | 3: CFZ 15 mg/m² + LEN 20 mg | 2: CFZ 15 mg/m² + LEN 15 mg | 1: CFZ 15 mg/m² + LEN 10 mg |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 61.9 years STANDARD_DEVIATION 9.86 | 62.4 years STANDARD_DEVIATION 10.75 | 65.4 years STANDARD_DEVIATION 7.85 | 57.7 years STANDARD_DEVIATION 9.31 | 61.7 years STANDARD_DEVIATION 6.68 | 55.4 years STANDARD_DEVIATION 7.74 | 64.2 years STANDARD_DEVIATION 12.11 | 64.7 years STANDARD_DEVIATION 6.65 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 0 (Fully active) | 33 participants | 23 participants | 2 participants | 2 participants | 1 participants | 3 participants | 0 participants | 2 participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 1 (Restrictive but ambulatory) | 46 participants | 17 participants | 6 participants | 4 participants | 5 participants | 5 participants | 5 participants | 4 participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 2 (Ambulatory but unable to work) | 5 participants | 4 participants | 0 participants | 0 participants | 0 participants | 0 participants | 1 participants | 0 participants |
| Race/Ethnicity, Customized African American | 9 participants | 3 participants | 0 participants | 1 participants | 2 participants | 1 participants | 2 participants | 0 participants |
| Race/Ethnicity, Customized Asian/Pacific Islander | 3 participants | 2 participants | 0 participants | 0 participants | 0 participants | 0 participants | 1 participants | 0 participants |
| Race/Ethnicity, Customized Caucasian | 64 participants | 34 participants | 7 participants | 5 participants | 2 participants | 7 participants | 3 participants | 6 participants |
| Race/Ethnicity, Customized Hispanic | 7 participants | 4 participants | 1 participants | 0 participants | 2 participants | 0 participants | 0 participants | 0 participants |
| Race/Ethnicity, Customized Other | 1 participants | 1 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Sex: Female, Male Female | 36 Participants | 18 Participants | 3 Participants | 3 Participants | 4 Participants | 3 Participants | 4 Participants | 1 Participants |
| Sex: Female, Male Male | 48 Participants | 26 Participants | 5 Participants | 3 Participants | 2 Participants | 5 Participants | 2 Participants | 5 Participants |
| Time Since Diagnosis | 3.1 years | 2.8 years | 4.3 years | 3.5 years | 2.8 years | 3.9 years | 2.4 years | 3.3 years |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 6 / 6 | 6 / 6 | 8 / 8 | 6 / 6 | 6 / 6 | 8 / 8 | 42 / 44 |
| serious Total, serious adverse events | 3 / 6 | 3 / 6 | 4 / 8 | 4 / 6 | 3 / 6 | 6 / 8 | 22 / 44 |
Outcome results
Primary
Number of Participants With Adverse Events (AEs)
Treatment-related are those AEs with possible or probable relationship to carfilzomib, lenalidomide or dexamethasone as assessed by the Investigator. The severity of each adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, per the following: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Serious adverse events were defined as AEs meeting one of the following: death, life-threatening, required or prolonged in-patient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in the offspring of an exposed participant, important medical events that may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above, or pregnancy or suspected pregnancy.
Time frame: From the first dose of study drug until 30 days after the last dose; 1 to 52 months, with an average of 12 months.
Population: Safety population consisting of all treated participants
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Adverse Events (AEs) | Treatment-related adverse event | 4 participants |
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of carfilzomib | 0 participants |
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Adverse Events (AEs) | Grade 3 or higher adverse event | 5 participants |
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of any study drug | 1 participants |
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Adverse Events (AEs) | Serious adverse event | 3 participants |
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Adverse Events (AEs) | Treatment-related Grade 3 or higher adverse event | 1 participants |
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Adverse Events (AEs) | Deaths within 30 days of last dose of study drug | 0 participants |
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Adverse Events (AEs) | Any adverse event | 6 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Adverse Events (AEs) | Grade 3 or higher adverse event | 6 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of any study drug | 1 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Adverse Events (AEs) | Treatment-related adverse event | 5 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Adverse Events (AEs) | Deaths within 30 days of last dose of study drug | 0 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Adverse Events (AEs) | Any adverse event | 6 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of carfilzomib | 0 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Adverse Events (AEs) | Treatment-related Grade 3 or higher adverse event | 4 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Adverse Events (AEs) | Serious adverse event | 3 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Deaths within 30 days of last dose of study drug | 0 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Grade 3 or higher adverse event | 8 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of any study drug | 3 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Serious adverse event | 4 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Any adverse event | 8 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of carfilzomib | 1 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Treatment-related Grade 3 or higher adverse event | 7 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Treatment-related adverse event | 8 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Treatment-related Grade 3 or higher adverse event | 4 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Grade 3 or higher adverse event | 6 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Serious adverse event | 4 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of carfilzomib | 2 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Deaths within 30 days of last dose of study drug | 0 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Any adverse event | 6 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | Treatment-related adverse event | 4 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of any study drug | 4 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Any adverse event | 6 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Deaths within 30 days of last dose of study drug | 0 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Treatment-related adverse event | 6 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Grade 3 or higher adverse event | 6 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Treatment-related Grade 3 or higher adverse event | 6 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Serious adverse event | 3 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of any study drug | 2 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of carfilzomib | 1 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of any study drug | 3 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Any adverse event | 8 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Treatment-related Grade 3 or higher adverse event | 8 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Grade 3 or higher adverse event | 8 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Treatment-related adverse event | 8 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Deaths within 30 days of last dose of study drug | 0 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Serious adverse event | 6 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of carfilzomib | 1 participants |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Deaths within 30 days of last dose of study drug | 3 participants |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Any adverse event | 44 participants |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Treatment-related adverse event | 43 participants |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Treatment-related Grade 3 or higher adverse event | 38 participants |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Serious adverse event | 22 participants |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of any study drug | 18 participants |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | AE leading to discontinuation of carfilzomib | 9 participants |
| 7: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Adverse Events (AEs) | Grade 3 or higher adverse event | 41 participants |
Primary
Number of Participants With Dose-limiting Toxicities
Dose-limiting toxicity was defined as any of the following events assessed as related to carfilzomib, lenalidomide, or dexamethasone: Nonhematologic * ≥ Grade 2 neuropathy with pain * ≥ Grade 3 nonhematologic toxicity (excluding nausea, vomiting, diarrhea, hyperglycemia due to dexamethasone, and rash due to lenalidomide) * ≥ Grade 3 nausea, vomiting, or diarrhea uncontrolled by maximal supportive therapy * ≥ Grade 4 fatigue persisting \> 7 days * Treatment delay for toxicity \> 21 days Hematologic * Grade 4 neutropenia (absolute neutrophil count \[ANC\] \< 500/mm³) \> 7 days * Febrile neutropenia (ANC \< 1,000/mm³ with fever ≥ 38.3ºC) * Grade 4 thrombocytopenia (platelets \< 25,000/mm³) for \> 7 days despite holding treatment, or Grade 3 or 4 thrombocytopenia associated with bleeding * Treatment delay for toxicity \> 21 days. The maximum-tolerated dose was defined as the dose level below which a drug-related DLT was observed in ≥ 33% of participants in a cohort.
Time frame: Cycle 1, 28 days
Population: Safety population for the dose escalation portion of the study
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 1: CFZ 15 mg/m² + LEN 10 mg | Number of Participants With Dose-limiting Toxicities | 0 participants |
| 2: CFZ 15 mg/m² + LEN 15 mg | Number of Participants With Dose-limiting Toxicities | 0 participants |
| 3: CFZ 15 mg/m² + LEN 20 mg | Number of Participants With Dose-limiting Toxicities | 0 participants |
| 4: CFZ 20 mg/m² + LEN 20 mg | Number of Participants With Dose-limiting Toxicities | 0 participants |
| 5: CFZ 20 mg/m² + LEN 25 mg | Number of Participants With Dose-limiting Toxicities | 0 participants |
| 6: CFZ 20/27 mg/m² + LEN 25 mg | Number of Participants With Dose-limiting Toxicities | 1 participants |